Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN CR versus VALMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN CR versus VALMID.
AMBIEN CR vs VALMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBIEN CR's active ingredient is zolpidem, a non-benzodiazepine hypnotic that binds selectively to the benzodiazepine-1 (BZ1) receptor subtype on the GABA-A receptor complex, potentiating GABAergic inhibition and promoting sleep.
Valproate increases gamma-aminobutyric acid (GABA) concentrations in the brain either by inhibiting GABA transaminase or by increasing glutamic acid decarboxylase activity, thereby enhancing inhibitory neurotransmission.
12.5 mg orally once daily immediately before bedtime; lower dose of 6.25 mg may be considered. Not to exceed 12.5 mg per day.
250 mg orally three times daily.
None Documented
None Documented
Zolpidem immediate-release: ~2.5 h (range 1.4–3.8 h); modified-release (Ambien CR): ~2.8 h (range 1.6–4.5 h). Clinical note: Half-life increased in hepatic impairment and elderly.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal (80% as metabolites, <5% unchanged), minor fecal (<10%)
Renal excretion accounts for >90% of elimination, primarily as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic